Introduction {#section5-0269881118788826}
============

Major depressive disorder (MDD) is characterized by multiple debilitating symptoms, spanning emotional, physical and cognitive domains, with serious consequences for patients' psychosocial and occupational functioning. Core symptoms of MDD include a persistent disturbance of mood and loss of interest/pleasure in most daily activities ([@bibr55-0269881118788826]). Patients may also experience physical symptoms such as fatigue/low energy, sleep and appetite disturbances, muscle tension, headaches, and general symptoms of pain, and cognitive symptoms such as impaired concentration, poor memory and difficulty in making decisions ([@bibr3-0269881118788826]; [@bibr62-0269881118788826]).

Full functional recovery is the ultimate treatment goal for patients with MDD, but many patients do not achieve even the more limited goal of full remission of depressive symptoms ([@bibr56-0269881118788826]): meta-analyses of controlled clinical studies indicate that only 30--50% of patients achieve remission after 6--8 weeks of antidepressant treatment ([@bibr65-0269881118788826]). Patients in partial remission may still have debilitating symptoms such as insomnia, anxiety, anhedonia, apathy and memory/concentration difficulties ([@bibr14-0269881118788826]; [@bibr49-0269881118788826]; [@bibr50-0269881118788826]). The presence of residual depressive symptoms partly accounts for the prevention of full functional recovery ([@bibr37-0269881118788826]), and predicts earlier relapse, recurrence and a more chronic course of illness ([@bibr37-0269881118788826], [@bibr38-0269881118788826]; [@bibr42-0269881118788826]).

Physical symptoms are commonly observed in patients with MDD. Depressive disorder with physical (somatic) symptoms may be the most common presentation of depression in inpatient and outpatient settings ([@bibr39-0269881118788826]). In studies reported by [@bibr22-0269881118788826] and [@bibr45-0269881118788826], about 80--90% of patients experienced physical symptoms, especially somatic anxiety and fatigue ([@bibr22-0269881118788826]; [@bibr45-0269881118788826]). Further, in a meta-analysis of 14 studies of patients with depression, 65% reported pain symptoms ([@bibr4-0269881118788826]). In addition, in a separate study by [@bibr14-0269881118788826], physical symptoms of sleepiness/sedation were reported by over 40% of patients who responded to and were continuing with long-term antidepressant treatment ([@bibr14-0269881118788826]).

The common clinical focus on the psychological symptoms of depression may obscure diagnosis in patients primarily presenting with physical symptoms, emphasizing the importance of careful clinical examination to avoid missing a diagnosis of depression ([@bibr58-0269881118788826]). The presence of somatic symptoms has a detrimental effect on the course and response to treatment ([@bibr19-0269881118788826]). Evidence also suggests that patients with somatic symptoms have a more chronic course of MDD and greater risk of comorbid anxiety disorders ([@bibr18-0269881118788826]; [@bibr35-0269881118788826]).

Vortioxetine has a multimodal mechanism of action (i.e., direct modulation of receptor activity and inhibition of the serotonin transporter) and has been approved for the treatment of MDD ([@bibr60-0269881118788826]). The efficacy and safety of vortioxetine in MDD was established as part of an extensive clinical development programme, which comprised 17 short-term placebo-controlled studies, six open-label long-term extension studies and one long-term relapse--prevention study, involving more than 9700 patients and a total exposure of over 3450 patient-years ([@bibr5-0269881118788826], [@bibr6-0269881118788826]; [@bibr15-0269881118788826]; [@bibr52-0269881118788826]).

Vortioxetine significantly improves depressive symptoms as measured by the Montgomery--Åsberg Depression Rating Scale (MADRS) or by the 24-item version of the Hamilton Depression Rating Scale (HAM-D) at doses between 5 and 20 mg daily ([@bibr41-0269881118788826]). Pooled analyses of data from short-term studies reveal significantly higher response and remission rates with vortioxetine when compared with placebo ([@bibr9-0269881118788826]; [@bibr41-0269881118788826]). Further, meta-analyses of effects of vortioxetine on the single items of the MADRS scale indicate its favourable effects across a broad range of depressive symptoms ([@bibr63-0269881118788826]).

Favourable effects of vortioxetine extend beyond emotional symptoms. In short-term controlled studies within the 5--20 mg dose range, vortioxetine significantly improves cognitive function (executive function, processing speed and attention/concentration) as compared to placebo, as measured by the Digit Symbol Substitution Test in patients with MDD ([@bibr48-0269881118788826]; [@bibr51-0269881118788826]). In addition, meta-analyses of short-term (6--8 week) studies in the same dosing range indicate improved overall functioning and functional remission, as measured by the Sheehan Disability Scale in adult MDD patients ([@bibr10-0269881118788826]; [@bibr17-0269881118788826]; [@bibr64-0269881118788826]), and significant and clinically meaningful improvements in health-related quality of life ([@bibr10-0269881118788826]; [@bibr15-0269881118788826]).

So far, only limited data have been published specifically addressing the effects of vortioxetine on depression-related physical symptoms. We therefore undertook post hoc analyses of data from five short-term, placebo-controlled studies of vortioxetine in patients with MDD. We chose these studies because both the 24-item HAM-D ([@bibr21-0269881118788826]; [@bibr59-0269881118788826]) and the Hamilton Anxiety Rating Scale (HAM-A) ([@bibr20-0269881118788826]) were employed; these scales cover a broad range of physical symptoms, permitting a more detailed assessment of potential effects within this domain.

Materials and methods {#section6-0269881118788826}
=====================

*Clinical studies*: All short-term studies where efficacy of vortioxetine on both the HAM-D and HAM-A were investigated in a comparable adult MDD population were included in this analysis. This comprised five short-term (6- or 8-week duration), randomized, double-blind, placebo-controlled, multi-centre studies evaluating the efficacy of vortioxetine versus placebo in adults with MDD ([Table 1](#table1-0269881118788826){ref-type="table"}). Study NCT00735709 ([@bibr26-0269881118788826]) investigated fixed doses of 1, 5 and 10 mg/day vortioxetine. Study NCT00839423 ([@bibr2-0269881118788826]) investigated fixed doses of 5 and 10 mg/day vortioxetine. Study NCT00635219 ([@bibr8-0269881118788826]) investigated fixed doses of 2.5, 5 and 10 mg/day vortioxetine, study NCT00672958 ([@bibr34-0269881118788826]) investigated a fixed dose of 5 mg/day vortioxetine and study NCT00672620 ([@bibr47-0269881118788826]) investigated fixed doses of 2.5 and 5 mg/day vortioxetine. From these studies, only patients treated with a dose within the therapeutic dose range (i.e. 5 or 10 mg/day) or placebo were considered for this analysis. All studies employed the MADRS, the 24-item HAM-D and the HAM-A as efficacy endpoints. The study population was defined as adults (aged 18‒75 years) with a primary diagnosis of MDD according to DSM IV-TR criteria, a current major depressive episode (MDE) of ⩾3 months' duration (confirmed using the Mini International Neuropsychiatric Interview ([@bibr61-0269881118788826])) and a Montgomery--Åsberg Depression Rating Scale (MADRS) total score of ⩾ 22, 26 or 30 at screening and baseline visits ([@bibr2-0269881118788826]; [@bibr8-0269881118788826]; [@bibr26-0269881118788826]; [@bibr34-0269881118788826]; [@bibr47-0269881118788826]).

###### 

Summary characteristics of the five short-term, placebo-controlled studies of vortioxetine in patients with MDD included in the meta-analyses.

![](10.1177_0269881118788826-table1)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NCT identifier    Treatment period (weeks)   Dose(s) of vortioxetine tested (mg/day)^[a](#table-fn1-0269881118788826){ref-type="table-fn"}^   Key inclusion criteria for MDD   Literature citation
  ----------------- -------------------------- ------------------------------------------------------------------------------------------------ -------------------------------- --------------------------------
  **NCT00839423**   6                          5 or 10                                                                                          Between 18 and 65 years\         **[@bibr2-0269881118788826]**
                                                                                                                                                MADRS total score ⩾30            

  **NCT00635219**   8                          2.5, 5 or 10                                                                                     Between 18 and 75 years\         **[@bibr8-0269881118788826]**
                                                                                                                                                MADRS total score ⩾26            

  **NCT00735709**   8                          1,5 or 10                                                                                        Between 18 and 75 years\         **[@bibr26-0269881118788826]**
                                                                                                                                                MADRS total score ⩾26            

  **NCT00672958**   6                          5                                                                                                Between 18 and 75 years\         **[@bibr34-0269881118788826]**
                                                                                                                                                MADRS total score ⩾30            

  **NCT00672620**   8                          2.5 or 5                                                                                         Between 18 and 75 years\         **[@bibr47-0269881118788826]**
                                                                                                                                                MADRS total score ⩾22            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

For the post hoc meta-analyses, only the 5 and 10 mg doses, approved as per current prescribing information, were included.

Detailed descriptions of the five clinical trial designs, methods and primary efficacy analyses have been published ([@bibr2-0269881118788826]; [@bibr8-0269881118788826]; [@bibr26-0269881118788826]; [@bibr34-0269881118788826]; [@bibr47-0269881118788826]). All trials were conducted according to the principles of Good Clinical Practice ([@bibr30-0269881118788826]) the Declaration of Helsinki ([@bibr67-0269881118788826]), and adhered to the requirements of all applicable local or regional regulations.

The meta-analysis did not include the long-term open-label studies, nor the dedicated study in elderly patients with MDD, or the study conducted for regulatory submission in Japan. The open-label studies ([@bibr1-0269881118788826]; [@bibr7-0269881118788826]; [@bibr16-0269881118788826]; [@bibr31-0269881118788826]) were excluded as these by definition do not have a comparator and thus prevent establising efficacy. The dedicated elderly study ([@bibr40-0269881118788826]) and the Japanese study ([@bibr29-0269881118788826]) were excluded as they did not include comparable study populations to the five global studies conducted in an adult MDD population; thus preventing a pooled analysis.

*Clinical assessments*: Complete details of all study assessments in the five studies are provided in [@bibr2-0269881118788826], [@bibr8-0269881118788826], [@bibr26-0269881118788826], [@bibr34-0269881118788826] and [@bibr47-0269881118788826]. This analysis is based on HAM-D items assessing the physical symptoms of depression, namely insomnia (early (item 4), middle (item 5) and late (item 6)), anxiety somatic (item 11), somatic symptoms gastrointestinal (item 12), somatic symptoms general (include both muscular pain, headache and lack of energy) (item 13), genital symptoms (include both loss of libido and menstrual disturbances) (item 14) and loss of weight (item 16) ([@bibr13-0269881118788826]; [@bibr21-0269881118788826]; [@bibr28-0269881118788826]), as well as the physical symptoms measured by the HAM-A, namely items of general somatic symptoms (muscular pain) (item 7), general somatic symptoms (sensory) (item 8), cardiovascular symptoms (item 9), respiratory symptoms (item 10), gastrointestinal symptoms (item 11), genitourinary symptoms (item 12) and autonomic symptoms (item 13) ([@bibr23-0269881118788826]).

*Statistical analysis*: To investigate the efficacy of vortioxetine on the physical symptoms of depression, a meta-analysis was performed, including data from all five studies. The statistical analyses were based on the full analysis set (FAS), as defined in each study separately. All statistical tests were two-sided. Nominal *p*-values less than 5% were considered statistically significant. Changes from baseline in HAM-D and HAM-A single items were, for each study and item separately, analyzed using a mixed model for repeated measurements (MMRM) approach, including treatment and site as factors and baseline value as covariate, with treatment-by-week and baseline-by-week interactions, and using an unstructured variance--covariance matrix. The MMRM analyses included all dose groups included in each study, but results were re-analyzed to align the model across studies before applying the meta-analysis. Standard random effects meta-analyses were carried out using the HAM-D and HAM-A results from the studies, and standardized mean differences to placebo were derived. The standardized estimates (SES) were obtained by applying a Cohen's D approach in the MMRM setting, with the relevant denominator being derived directly from the MMRM standard error to obtain the same *p*-values for the SES as for the original estimates.

The same meta-analysis was repeated but only including the data from the three studies -- NCT00839423, NCT00635219 and NCT00735709 -- that separated from placebo on the primary endpoint using the same analysis applied in our research, namely MMRM ([@bibr2-0269881118788826]; [@bibr8-0269881118788826]; [@bibr26-0269881118788826]). As the 10 mg dose was only investigated in these three studies, the results for the 10 mg group are identical to those in the meta-analysis considering all five studies. In addition, patients with a significant level of anxiety symptoms (i.e. those with a HAM-A ⩾20 at baseline) were analyzed as a subgroup. MDD patients with coexisting anxiety symptoms are not only common but typically also more difficult to treat than MDD patients without prominent anxiety, hence form a clinically relevant subgroup for this analysis ([@bibr27-0269881118788826]).

The trial was registered at [ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT00839423, NCT00635219, NCT00735709, NCT00672958, NCT00672620.

Results {#section7-0269881118788826}
=======

*Baseline characteristics*: Across studies, a total of 2105 patients were randomized to double-blind treatment with placebo (*n* = 850), vortioxetine 5 mg (*n* = 861) or vortioxetine 10 mg (*n* = 394). Of these, 2089 received study medication and 1729 completed the 6/8-week treatment period. Premature discontinuation rates were 17.7%, 16.6% and 17.7% in the placebo, vortioxetine 5 mg and vortioxetine 10 mg groups, respectively, across studies.

Demographic and baseline clinical characteristics of the study population in all five studies are summarized in [Table 2](#table2-0269881118788826){ref-type="table"}. Baseline demographic and clinical characteristics were similar across treatment groups. In the five studies patients had a mean age of approximately 44 years, all groups comprised a greater proportion of women than men and patients were predominantly Caucasian. The mean baseline MADRS total score and HAM-A total score were approximately 32 and 21, respectively, across all treatment groups in all five studies indicating a patient population with moderate to severe MDD and a significant level of anxiety.

###### 

Demographic and baseline characteristics (all randomized patients).

![](10.1177_0269881118788826-table2)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                                                    **All studies**\                                                                                
                                                                                              (NCT00839423, NCT00635219, NCT00735709, NCT00672958, NCT00672620)                               
  ------------------------------------------------------------------------------------------- ------------------------------------------------------------------- ------------- ------------- -------------
  **Age, years**                                                                                                                                                                              

  Mean (SD)                                                                                   43.3 (12.6)                                                         43.9 (13.0)   44.9 (12.9)   43.8 (12.8)

  Range                                                                                       18-75                                                               18-75         18-75         18-75

  **Gender,** *n* (%)                                                                                                                                                                         

  Male                                                                                        333 (39.2)                                                          306 (35.5)    141 (35.8)    780 (37.1)

  Female                                                                                      517 (60.8)                                                          555 (64.5)    253 (64.2)    1325 (62.9)

  **Race** (grouped) *n* (%)                                                                                                                                                                  

  Caucasian                                                                                   673 (79.2)                                                          662 (76.9)    321 (81.5)    1656 (78.7)

  Black                                                                                       112 (13.2)                                                          125 (14.5)    6 (1.5)       243 (11.5)

  Asian                                                                                       61 (7.2)                                                            69 (8.0)      64 (16.2)     194 (9.2)

  American                                                                                    3 (0.4)                                                             1 (0.1)       0             4 (0.2)

  1 (0.1)                                                                                     2 (0.2)                                                             3 (0.8)       6 (0.3)       

  **BMI, kg/m** ^2^                                                                                                                                                                           

  Mean (SD)                                                                                   28.3 (6.9)                                                          28.4 (7.5)    25.5 (4.8)    27.8 (6.9)

  **No. previous MDEs**                                                                                                                                                                       

  Mean (SD)                                                                                   2.3 (2.6)                                                           2.4 (3.1)     1.7 (2.1)     2.2 (2.7)

  Range                                                                                       0--23                                                               0--45         0--20         0--45

  **Duration of current MDE, weeks**                                                                                                                                                          

  Mean (SD)                                                                                   35.5 (57.4)                                                         40.8 (92.0)   30.6 (64.3)   36.8 (74.7)

  **MADRS total score**                                                                                                                                                                       

  Mean (SD)                                                                                   32.3 (4.0)                                                          32.6 (4.1)    32.3 (3.7)    32.4 (4.0)

  **CGI-S score**                                                                                                                                                                             

  Mean (SD)                                                                                   4.8 (0.7)                                                           4.8 (0.7)     4.9 (0.7)     4.8 (0.7)

  **HAM-D,** mean (SD)                                                                                                                                                                        

  Item 4: Insomnia Early^[1](#table-fn2-0269881118788826){ref-type="table-fn"}^               1.5 (0.7)                                                           1.5 (0.8)     1.5 (0.7)     1.5 (0.8)

  Item 5: Insomnia Middle^[2](#table-fn3-0269881118788826){ref-type="table-fn"}^              1.5 (0.7)                                                           1.5 (0.7)     1.5 (0.7)     1.5 (0.7)

  Item 6: Insomnia Late^[3](#table-fn4-0269881118788826){ref-type="table-fn"}^                1.4 (0.8)                                                           1.3 (0.8)     1.3 (0.7)     1.3 (0.8)

  Item 11: Anxiety Somatic^[4](#table-fn5-0269881118788826){ref-type="table-fn"}^             1.6 (0.8)                                                           1.6 (0.8)     1.7 (0.7)     1.6 (0.8)

  Item 12: Somatic Symptoms:\                                                                 0.8 (0.6)                                                           0.8 (0.6)     0.8 (0.6)     0.8 (0.6)
  Gastrointestinal^[5](#table-fn6-0269881118788826){ref-type="table-fn"}^                                                                                                                     

  Item 13: Somatic Symptoms: General^[6](#table-fn7-0269881118788826){ref-type="table-fn"}^   1.6 (0.6)                                                           1.6 (0.6)     1.5 (0.6)     1.6 (0.6)

  Item 14: Genital Symptoms^[7](#table-fn8-0269881118788826){ref-type="table-fn"}^            1.3 (0.8)                                                           1.3 (0.8)     1.2 (0.8)     1.3 (0.8)

  Item 16: Loss of Weight^[8](#table-fn9-0269881118788826){ref-type="table-fn"}^              0.3 (0.7)                                                           0.3 (0.7)     0.5 (0.7)     0.4 (0.7)

  Total score (24 items)                                                                      31.0 (5.5)                                                          31.5 (5.6)    31.1 (5.5)    31.2 (5.5)

  **HAM-A,** Mean (SD)                                                                                                                                                                        

  Item 7: Somatic Muscular^[9](#table-fn10-0269881118788826){ref-type="table-fn"}^            1.2 (0.9)                                                           1.2 (0.9)     1.3 (0.9)     1.3 (0.9)

  Item 8: Somatic Sensory^[10](#table-fn11-0269881118788826){ref-type="table-fn"}^            0.8 (0.9)                                                           0.8 (0.9)     1.1 (0.9)     0.9 (0.9)

  Item 9: Cardiovascular^[11](#table-fn12-0269881118788826){ref-type="table-fn"}^             0.8 (0.9)                                                           0.7 (0.9)     1.1 (0.9)     0.8 (0.9)

  Item 10: Respiratory^[12](#table-fn13-0269881118788826){ref-type="table-fn"}^               0.7 (0.8)                                                           0.7 (0.8)     0.9 (0.9)     0.7 (0.8)

  Item 11: Gastrointestinal^[13](#table-fn14-0269881118788826){ref-type="table-fn"}^          1.0 (0.9)                                                           1.0 (0.9)     1.3 (0.9)     1.1 (0.9)

  Item 12: Genitourinary^[14](#table-fn15-0269881118788826){ref-type="table-fn"}^             1.5 (1.1)                                                           1.5 (1.0)     1.5 (1.0)     1.5 (1.0)

  Item 13: Autonomic^[15](#table-fn16-0269881118788826){ref-type="table-fn"}^                 1.2 (0.9)                                                           1.1 (0.9)     1.3 (0.9)     1.2 (0.9)

  Total score                                                                                 20.4 (6.3)                                                          20.3 (6.1)    22.3 (6.6)    20.7 (6.3)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Item 4: Insomnia Early = complains of occasional difficulty falling asleep, i.e. more than ½ hour, or complains of nightly difficulty falling asleep;

Item 5: Insomnia Middle = patient complains of being restless and disturbed during the night or waking during the night;

Item 6: Insomnia Late = waking in early hours of the morning but goes back to sleep or unable to fall asleep again if getting out of bed;

Item 11: Anxiety Somatic = physiological concomitants of anxiety, such as gastrointestinal -- dry mouth, wind, indigestion, diarrhoea, cramps, belching, cardiovascular (palpitations, headache), respiratory (hyperventilation, sighing, urinary frequency, sweating);

Item 12: Somatic Symptoms -- Gastrointestinal = loss of appetite but eating without staff encouragement, heavy feelings in abdomen, difficulty eating without staff urging, requests or requires laxatives or medication for bowels or medication for GI symptoms;

Item 13: Somatic Symptoms -- General = heaviness in limbs, back or head, backaches, headache, muscle aches, loss of energy and fatigability;

Item 14: Genital Symptoms = symptoms such as loss of libido or menstrual disturbances;

Item 16: Loss of Weight = probable weight loss associated with present illness or definite (according to patient) weight loss.

HAM-A: ^9^Item 7: Somatic Muscular = includes weakness, stiffness, soreness merging into real pain, which is more or less diffusely localized in the muscles;

Item 8: Somatic Sensory = includes increased fatigability and weakness merging into real functional disturbances of the senses;

Item 9: Cardiovascular = includes tachycardia, palpitations, oppression, chest pain, throbbing in the blood vessels and feelings of fainting;

Item 10: Respiratory = includes feelings of constriction or contraction in throat or chest, dyspnoea merging into choking sensations and sighing respiration;

Item 11: Gastrointestinal = includes difficulties in swallowing, "sinking" sensation of the stomach, dyspepsia (heartburn or burning sensations in the stomach, abdominal pains related to meals, fullness, nausea and vomiting), abdominal rumbling and diarrhoea;

Item 12: Genitourinary = includes non-organic or psychic symptoms such as frequent or more pressing passing of urine, menstrual irregularities, anorgasmia, dyspareunia, premature ejaculation, loss of erection;

Item 13: Autonomic = includes dryness of mouth, blushing or pallor, sweating and dizziness.

*Clinical outcomes*: In the analysis of the five studies (NCT00839423, NCT00635219, NCT00735709, NCT00672958 and NCT00672620), a significant effect of vortioxetine versus placebo was observed in change from baseline on the HAM-D items of early insomnia (10 mg), middle and late insomnia (5 and 10 mg), anxiety somatic (10 mg), somatic symptoms general (5 and 10 mg) and genital symptoms (10 mg) ([Table 3](#table3-0269881118788826){ref-type="table"}, [Figure 1](#fig1-0269881118788826){ref-type="fig"}). For physical symptoms as measured by the HAM-A scale, a significant effect of vortioxetine versus placebo was observed on the somatic muscular item (5 mg), genitourinary item (5 and 10 mg) and autonomic item (10 mg) ([Table 4](#table4-0269881118788826){ref-type="table"}). In the subgroup of MDD patients with a high baseline level of anxiety, a significant effect of vortioxetine versus placebo was observed on the HAM-D scale for insomnia early and middle (5 and 10 mg), insomnia late (5 mg), anxiety somatic (5 and 10 mg), somatic symptoms gastrointestinal (5 mg), somatic symptoms general (5 and 10 mg) and genital symptoms (5 and 10 mg) ([Table 5](#table5-0269881118788826){ref-type="table"}). For the HAM-A scale a significant effect was observed on the somatic muscular (5 mg) and genitourinary items (5 and 10 mg) in patients with coexisting anxiety ([Table 5](#table5-0269881118788826){ref-type="table"}).

###### 

Meta-analysis of change from baseline in HAM-D single items at week 6/8 (FAS, MMRM, SES).
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  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Item**                                                                                              **Treatment** ^[a](#table-fn17-0269881118788826){ref-type="table-fn"}^   **All studies analysis**\                                           **Three studies analysis**\                                                                        
                                                                                                                                                                                 (NCT00839423, NCT00635219, NCT00735709, NCT00672958, NCT00672620)   (NCT00839423, NCT00635219, NCT00735709)                                                            
  ----------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------- ----------------------------------------- --------- ------- ----- ------- ------ --------- ------- --
  **4: Insomnia Early** ^[b](#table-fn18-0269881118788826){ref-type="table-fn"}^                        Placebo                                                                  691                                                                 ·                                         ·         ·             338     ·      ·         ·       

  VOR 5 mg                                                                                              714                                                                      −0.16                                                               0.09                                      0.086     0.025   350   −0.28   0.08   \<0.001   0.358   

  VOR 10 mg                                                                                             324                                                                      −0.35                                                               0.08                                      \<0.001   0.386   324   −0.35   0.08   \<0.001   0.386   

  **5: Insomnia Middle** ^[b](#table-fn18-0269881118788826){ref-type="table-fn"}^                       Placebo                                                                  691                                                                 ·                                         ·         ·             338     ·      ·         ·       

  VOR 5 mg                                                                                              714                                                                      −0.15                                                               0.05                                      0.006     0.576   350   −0.23   0.08   0.003     0.985   

  VOR 10 mg                                                                                             324                                                                      −0.37                                                               0.08                                      \<0.001   0.815   324   −0.37   0.08   \<0.001   0.815   

  **6: Insomnia Late** ^[b](#table-fn18-0269881118788826){ref-type="table-fn"}^                         Placebo                                                                  691                                                                                                                                   338                              

  VOR 5 mg                                                                                              714                                                                      −0.20                                                               0.07                                      0.002     0.214   350   −0.29   0.09   \<0.001   0.269   

  VOR 10 mg                                                                                             324                                                                      −0.25                                                               0.12                                      0.038     0.088   324   −0.25   0.12   0.038     0.088   

  **11: Anxiety Somatic** ^[b](#table-fn18-0269881118788826){ref-type="table-fn"}^                      Placebo                                                                  691                                                                 ·                                         ·         ·             338     ·      ·         ·       

  VOR 5 mg                                                                                              714                                                                      −0.15                                                               0.08                                      0.059     0.078   350   −0.28   0.08   \<0.001   0.678   

  VOR 10 mg                                                                                             324                                                                      −0.32                                                               0.08                                      \<0.001   0.356   324   −0.32   0.08   \<0.001   0.356   

  **12: Somatic Symptoms: Gastrointestinal** ^[b](#table-fn18-0269881118788826){ref-type="table-fn"}^   Placebo                                                                  691                                                                 ·                                         ·         ·             338     ·      ·         ·       

  VOR 5 mg                                                                                              714                                                                      −0.11                                                               0.07                                      0.091     0.205   350   −0.23   0.08   0.003     0.908   

  VOR 10 mg                                                                                             324                                                                      −0.26                                                               0.18                                      0.153     0.005   324   −0.26   0.18   0.153     0.005   

  **13: Somatic Symptoms: General** ^[b](#table-fn18-0269881118788826){ref-type="table-fn"}^            Placebo                                                                  691                                                                 ·                                         ·         ·             338     ·      ·         ·       

  VOR 5 mg                                                                                              714                                                                      −0.17                                                               0.07                                      0.013     0.154   350   −0.28   0.08   \<0.001   0.411   

  VOR 10 mg                                                                                             324                                                                      −0.27                                                               0.08                                      \<0.001   0.408   324   −0.27   0.08   \<0.001   0.408   

  **14: Genital Symptoms** ^[b](#table-fn18-0269881118788826){ref-type="table-fn"}^                     Placebo                                                                  691                                                                 ·                                         ·         ·             338     ·      ·         ·       

  VOR 5 mg                                                                                              714                                                                      −0.20                                                               0.10                                      0.052     0.007   350   −0.37   0.08   \<0.001   0.853   

  VOR 10 mg                                                                                             324                                                                      −0.38                                                               0.08                                      \<0.001   0.803   324   −0.38   0.08   \<0.001   0.803   

  **16: Loss of Weight** ^[b](#table-fn18-0269881118788826){ref-type="table-fn"}^                       Placebo                                                                  691                                                                 ·                                         ·         ·             338     ·      ·         ·       

  VOR 5 mg                                                                                              714                                                                      −0.11                                                               0.08                                      0.208     0.050   350   −0.04   0.08   0.620     0.941   

  VOR 10 mg                                                                                             324                                                                      −0.09                                                               0.08                                      0.249     0.830   324   −0.09   0.08   0.249     0.830   

  **HAM-D24 total score**                                                                               Placebo                                                                  691                                                                                                                                   338                              

  VOR 5 mg                                                                                              714                                                                      −0.32                                                               0.11                                      0.003     0.004   350   −0.47   0.09   \<0.001   0.230   

  VOR 10 mg                                                                                             324                                                                      −0.58                                                               0.15                                      \<0.001   0.026   324   −0.58   0.15   \<0.001   0.026   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The 10 mg vortioxetine (VOR) dose was tested only in the three positive studies; thus, the data in the 10 mg dose rows for the 'All studies' and the 'Three studies' analyses are identical.

Definition of item provided in [Table 2](#table1-0269881118788826){ref-type="table"}.

![Change from baseline in HAM-D single items at week 6/8 (FAS, MMRM, SES) -- all five studies ([@bibr2-0269881118788826]; [@bibr8-0269881118788826]; [@bibr26-0269881118788826]; [@bibr34-0269881118788826]; [@bibr47-0269881118788826]). \**p*\<0.05; \*\**p*\<0.01; \*\*\**p*\<0.001. Definition of each item provided in [Table 2](#table2-0269881118788826){ref-type="table"}.](10.1177_0269881118788826-fig1){#fig1-0269881118788826}

###### 

Meta-analysis of change from baseline in HAM-A single items at week 6/8 (FAS, MMRM, SES).

![](10.1177_0269881118788826-table4)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Item**                                                                            **Treatment** ^[a](#table-fn19-0269881118788826){ref-type="table-fn"}^   **All studies analysis**\                                           **Three studies analysis**\                                                                        
                                                                                                                                                               (NCT00839423, NCT00635219, NCT00735709, NCT00672958, NCT00672620)   (NCT00839423, NCT00635219, NCT00735709)                                                            
  ----------------------------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------- ----------------------------------------- -------- ------- ----- ------- ------- --------- ------- --
  **7: Somatic Muscular** ^[b](#table-fn20-0269881118788826){ref-type="table-fn"}^    Placebo                                                                  695                                                                 ·                                         ·        ·             335     ·                         

  VOR 5 mg                                                                            711                                                                      −0.15                                                               0.06                                      0.021    0.239   344   −0.21   0.08    0.005     0.740   

  VOR 10 mg                                                                           319                                                                      −0.15                                                               0.08                                      0.055    0.837   319   −0.15   0.08    0.055     0.837   

  **8: Somatic Sensory** ^[b](#table-fn20-0269881118788826){ref-type="table-fn"}^     Placebo                                                                  695                                                                 ·                                         ·        ·             335     ·                         

  VOR 5 mg                                                                            711                                                                      −0.10                                                               0.05                                      0.052    0.866   344   −0.15   0.08    0.050     0.765   

  VOR 10 mg                                                                           319                                                                      −0.18                                                               0.11                                      0.126    0.121   319   −0.18   0.11    0.126     0.121   

  **9: Cardiovascular** ^[b](#table-fn20-0269881118788826){ref-type="table-fn"}^      Placebo                                                                  695                                                                 ·                                         ·        ·             335     ·                         

  VOR 5 mg                                                                            711                                                                      −0.04                                                               0.12                                      0.722    0.001   344   −0.18   0.11    0.097     0.140   

  VOR 10 mg                                                                           319                                                                      −0.17                                                               0.13                                      0.182    0.073   319   −0.17   0.13    0.182     0.073   

  **10: Respiratory** ^[b](#table-fn20-0269881118788826){ref-type="table-fn"}^        Placebo                                                                  694                                                                 ·                                         ·        ·             335     ·                         

  VOR 5 mg                                                                            711                                                                      −0.16                                                               0.09                                      0.074    0.035   344   −0.24   0.11    0.030     0.133   

  VOR 10 mg                                                                           319                                                                      −0.19                                                               0.11                                      0.084    0.131   319   −0.19   0.11    0.084     0.131   

  **11: Gastrointestinal** ^[b](#table-fn20-0269881118788826){ref-type="table-fn"}^   Placebo                                                                  695                                                                 ·                                         ·        ·             335     ·                         

  VOR 5 mg                                                                            711                                                                      −0.10                                                               0.05                                      0.060    0.540   344   −0.20   0.08    0.011     0.990   

  VOR 10 mg                                                                           319                                                                      −0.22                                                               0.12                                      0.069    0.089   319   −0.22   0.12    0.069     0.089   

  **12: Genitourinary** ^[b](#table-fn20-0269881118788826){ref-type="table-fn"}^      Placebo                                                                  695                                                                 ·                                         ·        ·             335     ·                         

  VOR 5 mg                                                                            711                                                                      −0.15                                                               0.06                                      0.020    0.251   344   −0.24   ·0.08   0.002     0.457   

  VOR 10 mg                                                                           319                                                                      −0.28                                                               0.08                                      \<.001   0.553   319   −0.28   0.08    \<0.001   0.553   

  **13: Autonomic** ^[b](#table-fn20-0269881118788826){ref-type="table-fn"}^          Placebo                                                                  695                                                                 ·                                         ·        ·             335     ·                         

  VOR 5 mg                                                                            711                                                                      −0.01                                                               0.07                                      0.897    0.206   344   −0.12   0.08    0.123     0.536   

  VOR 10 mg                                                                           319                                                                      −0.27                                                               0.12                                      0.025    0.103   319   −0.27   0.12    0.025     0.103   

  **HAM-A total score**                                                               Placebo                                                                  695                                                                                                                                  335                               

  VOR 5 mg                                                                            711                                                                      −0.25                                                               0.10                                      0.012    0.012   344   −0.39   0.08    \<0.001   0.370   

  VOR 10 mg                                                                           319                                                                      −0.47                                                               0.12                                      \<.001   0.119   319   −0.47   0.12    \<0.001   0.119   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The 10 mg vortioxetine (VOR) dose was tested only in the three positive studies; thus, the data in the 10 mg dose rows for the 'All studies' and the 'Three studies' analyses are identical.

Definition of item provided in [Table 2](#table1-0269881118788826){ref-type="table"}.

###### 

Meta-analysis of change from baseline in HAM-D and HAM-A single items at week 6/8 in MDD patients with a high level of baseline anxiety (HAM-A total score ⩾20) (FAS, MMRM, SES).

![](10.1177_0269881118788826-table5)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Item**                                                                                              **Treatment** ^[a](#table-fn21-0269881118788826){ref-type="table-fn"}^   **All studies analysis**\                                           **Three studies analysis**\                                                                                                                  
                                                                                                                                                                                 (NCT00839423, NCT00635219, NCT00735709, NCT00672958, NCT00672620)   (NCT00839423, NCT00635219, NCT00735709)                                                                                                      
  ----------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------- ----------------------------------------- --------- --------------- -------------------- --------- --------------- --------- --------------- --------------------
  **HAM-D**                                                                                                                                                                                                                                                                                                                                                                                       

  **4: Insomnia Early** ^[b](#table-fn22-0269881118788826){ref-type="table-fn"}^                        Placebo                                                                  325                                                                 ·                                         ·         ·                                    196       ·               ·         ·               

  VOR 5 mg                                                                                              315                                                                      −0.20                                                               0.09                                      0.022     0.303           178                  −0.29     0.13            0.029     0.189           

  VOR 10 mg                                                                                             183                                                                      −0.23                                                               0.10                                      0.025     0.643           183                  −0.23     0.10            0.025     0.643           

  **5: Insomnia Middle** ^[b](#table-fn22-0269881118788826){ref-type="table-fn"}^                       Placebo                                                                  325                                                                 ·                                         ·         ·                                    196       ·               ·         ·               

  VOR 5 mg                                                                                              315                                                                      −0.19                                                               0.08                                      0.018     0.772           178                  −0.24     0.10            0.022     0.614           

  VOR 10 mg                                                                                             183                                                                      −0.39                                                               0.10                                      \<0.001   0.652           183                  −0.39     0.10            \<0.001   0.652           

  **6: Insomnia Late** ^[b](#table-fn22-0269881118788826){ref-type="table-fn"}^                         Placebo                                                                  325                                                                                                           ·         ·                                    196                       ·         ·               

  VOR 5 mg                                                                                              315                                                                      ·--0.26                                                             0.10                                      0.009     0.195           178                  −0.29     0.18            0.098     0.058           

  VOR 10 mg                                                                                             183                                                                      −0.19                                                               0.19                                      0.316     0.032           183                  −0.19     0.19            0.316     0.032           

  **11: Anxiety Somatic** ^[b](#table-fn22-0269881118788826){ref-type="table-fn"}^                      Placebo                                                                  325                                                                 ·                                         ·         ·                                    196       ·               ·         ·               

  VOR 5 mg                                                                                              315                                                                      −0.21                                                               0.10                                      0.039     0.165           178                  −0.32     0.13            0.012     0.218           

  VOR 10 mg                                                                                             183                                                                      −0.26                                                               0.10                                      0.012     0.869           183                  −0.26     0.10            0.012     0.869           

  **12: Somatic Symptoms: Gastrointestinal** ^[b](#table-fn22-0269881118788826){ref-type="table-fn"}^   Placebo                                                                  325                                                                 ·                                         ·         ·                                    196       ·               ·         ·               

  VOR 5 mg                                                                                              315                                                                      −0.17                                                               0.08                                      0.032     0.555           178                  −0.17     0.13            0.168     0.230           

  VOR 10 mg                                                                                             183                                                                      −0.21                                                               0.20                                      0.315     0.021           183                  −0.21     0.20            0.315     0.021           

  **13: Somatic Symptoms: General** ^[b](#table-fn22-0269881118788826){ref-type="table-fn"}^            Placebo                                                                  325                                                                 ·                                         ·         ·                                    196       ·               ·         ·               

  VOR 5 mg                                                                                              315                                                                      −0.27                                                               0.08                                      0.002     0.341           178                  −0.33     0.10            0.001     0.591           

  VOR 10 mg                                                                                             183                                                                      −0.28                                                               0.10                                      0.006     0.617           183                  −0.28     0.10            0.006     0.617           

  **14: Genital Symptoms** ^[b](#table-fn22-0269881118788826){ref-type="table-fn"}^                     Placebo                                                                  325                                                                 ·                                         ·         ·                                    196       ·               ·         ·               

  VOR 5 mg                                                                                              315                                                                      −0.21                                                               0.08                                      0.007     0.692           178                  −0.30     0.10            0.004     0.776           

  VOR 10 mg                                                                                             183                                                                      −0.38                                                               0.10                                      \<0.001   0.929           183                  −0.38     0.10            \<0.001   0.929           

  **16: Loss of Weight** ^[b](#table-fn22-0269881118788826){ref-type="table-fn"}^                       Placebo                                                                  325                                                                 ·                                         ·         ·                                    196       ·               ·         ·               

  VOR 5 mg                                                                                              315                                                                      −0.11                                                               0.08                                      0.148     0.434           178                  −0.07     0.11            0.523     0.316           

  VOR 10 mg                                                                                             183                                                                      −0.13                                                               0.10                                      0.190     0.878           183                  −0.13     0.10            0.190     0.878           

  **HAM-D24 total score**                                                                               Placebo                                                                  325                                                                                                                                                          196                                                 

  VOR 5 mg                                                                                              315                                                                      −0.37                                                               0.11                                      0.001     0.088           178                  −0.49     0.18            0.005     0.060           

  VOR 10 mg                                                                                             183                                                                      −0.52                                                               0.18                                      0.004     0.044           183                  −0.52     0.18            0.004     0.044           

  **Item**                                                                                              **Treatment**                                                            ***N***                                                             ∆ **Placebo**                             **SE**    ***p*-value**   **Heterogeneity**\   ***N***   ∆ **Placebo**   **SE**    ***p*-value**   **Heterogeneity**\
                                                                                                                                                                                                                                                                                                                         ***p*-value**                                                            ***p*-value**

  **HAM-A**                                                                                                                                                                                                                                                                                                                                                                                       

  **7: Somatic Muscular** ^[b](#table-fn22-0269881118788826){ref-type="table-fn"}^                      Placebo                                                                  327                                                                 ·                                         ·         ·                                    196       ·               ·         ·               

  VOR 5 mg                                                                                              316                                                                      −0.20                                                               0.08                                      0.011     0.784           178                  −0.19     0.10            0.066     0.641           

  VOR 10 mg                                                                                             183                                                                      −0.06                                                               0.10                                      0.541     0.897           183                  −0.06     0.10            0.541     0.897           

  **8: Somatic Sensory** ^[b](#table-fn22-0269881118788826){ref-type="table-fn"}^                       Placebo                                                                  327                                                                 ·                                         ·         ·                                    196       ·               ·         ·               

  VOR 5 mg                                                                                              316                                                                      −0.11                                                               0.08                                      0.162     0.655           178                  −0.15     0.10            0.142     0.472           

  VOR 10 mg                                                                                             183                                                                      −0.11                                                               0.15                                      0.457     0.125           183                  −0.11     0.15            0.457     0.125           

  **9: Cardiovascular** ^[b](#table-fn22-0269881118788826){ref-type="table-fn"}^                        Placebo                                                                  327                                                                 ·                                         ·         ·                                    196                                                 

  VOR 5 mg                                                                                              316                                                                      −0.10                                                               0.14                                      0.476     0.017           178                  −0.23     0.14            0.088     0.182           

  VOR 10 mg                                                                                             183                                                                      −0.17                                                               0.14                                      0.237     0.154           183                  −0.17     0.14            0.237     0.154           

  **10: Respiratory** ^[b](#table-fn22-0269881118788826){ref-type="table-fn"}^                          Placebo                                                                  326                                                                 ·                                         ·         ·                                    196       ·               ·         ·               

  VOR 5 mg                                                                                              316                                                                      −0.14                                                               0.11                                      0.187     0.133           178                  −0.23     0.15            0.126     0.135           

  VOR 10 mg                                                                                             183                                                                      −0.24                                                               0.14                                      0.084     0.173           183                  −0.24     0.14            0.084     0.173           

  **11: Gastrointestinal** ^[b](#table-fn22-0269881118788826){ref-type="table-fn"}^                     Placebo                                                                  327                                                                 ·                                         ·         ·                                    196       ·               ·         ·               

  VOR 5 mg                                                                                              316                                                                      −0.12                                                               0.08                                      0.120     0.441           178                  −0.17     0.10            0.096     0.633           

  VOR 10 mg                                                                                             183                                                                      −0.27                                                               0.15                                      0.072     0.129           183                  −0.27     0.15            0.072     0.129           

  **12: Genitourinary** ^[b](#table-fn22-0269881118788826){ref-type="table-fn"}^                        Placebo                                                                  327                                                                 ·                                         ·         ·                                    196       ·               ·         ·               

  VOR 5 mg                                                                                              316                                                                      −0.17                                                               0.08                                      0.029     0.853           178                  −0.18     0.10            0.090     0.543           

  VOR 10 mg                                                                                             183                                                                      −0.25                                                               0.12                                      0.035     0.273           183                  −0.25     0.12            0.035     0.273           

  **13: Autonomic** ^[b](#table-fn22-0269881118788826){ref-type="table-fn"}^                            Placebo                                                                  327                                                                 ·                                         ·         ·                                    196       ·               ·         ·               

  VOR 5 mg                                                                                              316                                                                      −0.06                                                               0.09                                      0.536     0.246           178                  −0.16     0.14            0.244     0.179           

  VOR 10 mg                                                                                             183                                                                      −0.28                                                               0.16                                      0.077     0.098           183                  −0.28     0.16            0.077     0.098           

                                                                                                                                                                                                                                                                                                                                                                                                  

  **HAM-A total score**                                                                                 Placebo                                                                  327                                                                                                           0\.                                            196                                                 

  VOR 5 mg                                                                                              316                                                                      −0.28                                                               12                                        0.021     0.063           178                  −0.42     0.17            0.013     0.076           

  VOR 10 mg                                                                                             183                                                                      −0.44                                                               0.18                                      0.017     0.045           183                  −0.44     0.18            0.017     0.045           
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The 10 mg vortioxetine (VOR) dose was tested only in the three positive studies; thus, the data in the 10 mg dose rows for the 'All studies' and the 'Three studies' analyses are identical.

Definition of item provided in [Table 1](#table1-0269881118788826){ref-type="table"}.

In the analysis of the three studies NCT00839423, NCT00635219 and NCT00735709, a statistically significant improvement with vortioxetine (5 and 10 mg) versus placebo was observed in change from baseline on all three insomnia items of the HAM-D (insomnia early, middle and late), two somatic items (gastrointestinal (5 mg only) and general), anxiety somatic and genital symptoms ([Table 3](#table3-0269881118788826){ref-type="table"}, [Figure 2](#fig2-0269881118788826){ref-type="fig"}). For physical symptoms measured by the HAM-A scale, a significant improvement with vortioxetine versus placebo was observed on the somatic muscular, respiratory, and gastrointestinal items for 5 mg vortioxetine, genitourinary item (5 and 10 mg vortioxetine) and autonomic item (10 mg vortioxetine) ([Table 4](#table4-0269881118788826){ref-type="table"}, [Figure 3](#fig3-0269881118788826){ref-type="fig"}). A borderline significant effect was also observed on the somatic sensory item (*p*=0.05). In the subgroup of MDD patients with a high baseline level of anxiety, significant favourable effects versus placebo for both 5 and 10 mg vortioxetine were observed on the HAM-D items of early and middle insomnia, general somatic and somatic anxiety symptoms, and genital symptoms ([Table 5](#table5-0269881118788826){ref-type="table"}).

![Change from baseline in HAM-D single items at week 6/8 (FAS, MMRM, SES) -- three studies ([@bibr2-0269881118788826]; [@bibr8-0269881118788826]; [@bibr26-0269881118788826]). \**p*\<0.05; \*\**p*\<0.01; \*\*\**p*\<0.001. Definition of each item provided in [Table 2](#table2-0269881118788826){ref-type="table"}.](10.1177_0269881118788826-fig2){#fig2-0269881118788826}

![Change from baseline in HAM-A single items at week 6/8 (FAS, MMRM, SES) -- five studies ([@bibr2-0269881118788826]; [@bibr8-0269881118788826]; [@bibr26-0269881118788826]; [@bibr34-0269881118788826]; [@bibr47-0269881118788826]). \**p*\<0.05; \*\**p*\<0.01; \*\*\**p*\<0.001. Definition of each item provided in [Table 2](#table2-0269881118788826){ref-type="table"}.](10.1177_0269881118788826-fig3){#fig3-0269881118788826}

Discussion {#section8-0269881118788826}
==========

In this meta-analysis of five short-term randomized clinical trials in patients with MDD, vortioxetine significantly improved most of the physical symptoms of depression, as measured by the HAM-D and HAM-A. Further, in the subset of MDD patients with high baseline anxiety levels, improvements in physical symptoms were also observed.

The presence of physical symptoms in MDD patients is a significant predictor of a more chronic course of disease, with a lower probability of treatment response and remission of depressive symptoms ([@bibr18-0269881118788826]; [@bibr35-0269881118788826]). Residual physical symptoms may also increase the risk of recurrence ([@bibr19-0269881118788826]).

Since comorbid anxiety disorders are observed in a substantial proportion of MDD patients (with ranges of \~30--50% reported depending upon population sampled; [@bibr44-0269881118788826]), the efficacy of vortioxetine on the physical symptoms of depression in MDD patients with marked coexisting anxiety symptoms is encouraging. A recent meta-analysis of 10 short-term randomized, placebo-controlled trials of vortioxetine in MDD patients with high levels of anxiety indicated efficacy in reducing depressive and anxiety symptoms in this group of patients ([@bibr6-0269881118788826]). Together with the results reported here on the physical symptoms of depression, vortioxetine also seems to be a rational treatment option in patients with MDD and high anxiety, who often do not respond satisfactorily to alternative antidepressant therapy.

Although much remains uncertain about the pathophysiology of depression, abnormalities in serotonin (5-HT) and norepinephrine (NE) neurotransmission are probably involved in psychological and physical depressive symptoms ([@bibr13-0269881118788826]). Pain control, for instance, appears to be influenced by both 5-HT and NE; this is consistent with reports that their analgesic effects seem to be mediated via common descending pain pathways ([@bibr13-0269881118788826]; [@bibr36-0269881118788826]; [@bibr57-0269881118788826]; [@bibr66-0269881118788826]). The 5-HT~7~ receptor has been shown in preclinical studies to play a key role in regulation of circadian rhythmicity and sleep -- physiological functions that often are disturbed in patients with MDD ([@bibr25-0269881118788826]; [@bibr53-0269881118788826]). Non-clinical studies with vortioxetine have shown that the compound modulates several neurotransmitter systems, including GABAergic, glutamatergic, serotonergic, norepinephrinergic, dopaminergic, histaminergic and cholinergic systems through complex mechanisms involving SERT inhibition and modulation of several 5-HT receptor subtypes, including the 5-HT~7~ receptor ([@bibr60-0269881118788826]). Further, in rodent preclinical models of analgesic activity, vortioxetine showed potential for mitigating centrally mediated pain, though no activity was observed against inflammatory pain ([@bibr12-0269881118788826]). Modulation of neurotransmitters involved in neural pain pathways may mediate an analgesic response and consequently relief of painful physical symptoms associated with depression ([@bibr41-0269881118788826]; [@bibr46-0269881118788826]; [@bibr54-0269881118788826]).

Sexual dysfunction is a common physical symptom of depression as well as common side effect of many antidepressants. In the clinical development programme of vortioxetine, treatment-emergent sexual dysfunction (TESD) was prospectively captured by the Arizona Sexual Dysfunction Scale and compared with placebo. Vortioxetine 5--20 mg was associated with an approximately 5% increase in incidence of TESD, a relatively low level compared with other antidepressants ([@bibr33-0269881118788826]; [@bibr43-0269881118788826]). In a recent randomized, double-blind trial in which well-treated MDD patients experiencing selective serotonin reuptake inhibitor (SSRI)-related sexual dysfunction were switched to either vortioxetine or escitalopram, significant clinical improvements in sexual functioning were observed for vortioxetine versus escitalopram, thus confirming its clinical value for this specific yet important physical symptom of depression ([@bibr32-0269881118788826]).

Antidepressants with proven efficacy across multiple symptom domains may provide clinicians with important options to fill the existing unmet needs in the treatment of MDD. Vortioxetine has proven effective across a broad range of depressive symptoms as measured by MADRS or the HAM-D ([@bibr41-0269881118788826]). In addition, vortioxetine significantly improves cognitive symptoms known to be impacted in MDD such as executive function, attention/speed of processing and memory ([@bibr24-0269881118788826]; [@bibr51-0269881118788826]) as well as functional capacity ([@bibr11-0269881118788826]; [@bibr48-0269881118788826]). These improvements, along with beneficial effects on physical symptoms, may confer the MDD patient the best chance for a full functional recovery.

There are some limitations to these analyses that affect the interpretation of data. All analyses were conducted post hoc using data from five short-term studies originally designed to assess a different primary outcome. In these studies, the assessment of somatic symptoms was not a specific endpoint, nor was a specific scale used for the evaluation of somatic symptoms such as measures of pain or insomnia. Nevertheless, among the commonly used scales for measuring broad antidepressant effect in clinical registration trials such as the MADRS or HAM-D, the HAM-D captures the most physical symptoms of depression in a broad MDD population. Additionally, vortioxetine is an approved antidepressant in the dose range of 5, 10, 15 and 20 mg. The HAM-D scale was only used as a measure of antidepressant effect in the studies investigating the efficacy of vortioxetine 5 and 10 mg, and therefore this study could not investigate the efficacy on physical symptoms of depression at the doses 15 and 20 mg. Nevertheless, the clinical development programme for vortioxetine demonstrated a dose--response relationship for overall efficacy, and single-item analysis of the MADRS scale confirmed this dose--response relationship across the dose range ([@bibr63-0269881118788826]). Finally, our analysis is based on studies of short duration and study participants are not necessarily representative of patients with MDD in usual clinical practice.

In conclusion, the findings of these analyses indicate that patients with MDD (and patients with MDD and a high level of anxiety symptoms) can have significant improvements in MDD-associated physical symptoms during vortioxetine treatment. These findings are important in the treatment of MDD patients for the therapeutic goals of providing broad symptom relief and achieving full functional recovery.
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